BACKGROUND: HIV-infected children are at increased risk of developing invasive Streptococcus pneumoniae disease. OBJECTIVE: To determine the impact of the HIV epidemic on the epidemiology of invasive pneumococcal disease in hospitalized African children. METHODS: Children <12 years of age with invasive pneumococcal disease were enrolled between March, 1997, and February, 1999. RESULTS: The seroprevalence of HIV was 64.9% (146 of 225). In children with pneumococcal isolates from serogroups 6, 9, 14, 19 or 23 (pediatric serogroups), pneumonia and pneumonia with concurrent meningitis was more common in HIV-infected children (P = 0.03 and P = 0.003, respectively), whereas septic shock occurred more often in HIV-uninfected children (P = 0.0003). The overall burden of severe invasive pneumococcal disease was 41.7 (95% confidence interval, 26.5 to 65.6) fold increased in HIV-infected compared with HIV-uninfected children. Reduced susceptibility to penicillin (45.91% vs. 27.9%, P = 0.009), trimethoprim-sulfamethoxazole (44.5% vs. 19.0%, P = 0.0002) and multiple drug resistance was more common in HIV-infected than in HIV-uninfected children (24.0% vs. 6.4%, P = 0.01), respectively. The increased burden of disease and reduced antibiotic susceptibility of pneumococcal isolates in HIV-infected children was because of a heightened susceptibility to disease caused by pediatric serogroups in these children than in HIV-uninfected children (P = 0.01). Although the case fatality rates did not differ between HIV-infected and -uninfected children, mortality in HIV-infected children with advanced AIDS (Stage C, 22 of 61; 36.1%) was greater than that in children with moderate AIDS (Stage B, 12 of 85; 14.1%, P = 0.002). CONCLUSIONS: In children with invasive pneumococcal disease caused by the pediatric serogroups, HIV-infected children have more antibiotic-resistant isolates and have a different clinical presentation than do HIV-uninfected children.
BACKGROUND:HIV-infectedchildren are at increased risk of developing invasive Streptococcus pneumoniae disease. OBJECTIVE: To determine the impact of the HIV epidemic on the epidemiology of invasive pneumococcal disease in hospitalized African children. METHODS:Children <12 years of age with invasive pneumococcal disease were enrolled between March, 1997, and February, 1999. RESULTS: The seroprevalence of HIV was 64.9% (146 of 225). In children with pneumococcal isolates from serogroups 6, 9, 14, 19 or 23 (pediatric serogroups), pneumonia and pneumonia with concurrent meningitis was more common in HIV-infectedchildren (P = 0.03 and P = 0.003, respectively), whereas septic shock occurred more often in HIV-uninfectedchildren (P = 0.0003). The overall burden of severe invasive pneumococcal disease was 41.7 (95% confidence interval, 26.5 to 65.6) fold increased in HIV-infected compared with HIV-uninfectedchildren. Reduced susceptibility to penicillin (45.91% vs. 27.9%, P = 0.009), trimethoprim-sulfamethoxazole (44.5% vs. 19.0%, P = 0.0002) and multiple drug resistance was more common in HIV-infected than in HIV-uninfectedchildren (24.0% vs. 6.4%, P = 0.01), respectively. The increased burden of disease and reduced antibiotic susceptibility of pneumococcal isolates in HIV-infectedchildren was because of a heightened susceptibility to disease caused by pediatric serogroups in these children than in HIV-uninfectedchildren (P = 0.01). Although the case fatality rates did not differ between HIV-infected and -uninfected children, mortality in HIV-infectedchildren with advanced AIDS (Stage C, 22 of 61; 36.1%) was greater than that in children with moderate AIDS (Stage B, 12 of 85; 14.1%, P = 0.002). CONCLUSIONS: In children with invasive pneumococcal disease caused by the pediatric serogroups, HIV-infectedchildren have more antibiotic-resistant isolates and have a different clinical presentation than do HIV-uninfectedchildren.
Authors: Penny Crowther-Gibson; Cheryl Cohen; Keith P Klugman; Linda de Gouveia; Anne von Gottberg Journal: Antimicrob Agents Chemother Date: 2012-07-16 Impact factor: 5.191
Authors: George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim Journal: Pediatr Infect Dis J Date: 2013-11 Impact factor: 2.129
Authors: Enitan D Carrol; Limangeni A Mankhambo; Paul Balmer; Standwell Nkhoma; Daniel L Banda; Malcolm Guiver; Graham Jeffers; Nick Makwana; Elizabeth M Molyneux; Malcolm E Molyneux; Rosalind L Smyth; C Anthony Hart Journal: J Acquir Immune Defic Syndr Date: 2007-04-01 Impact factor: 3.731
Authors: Shabir A Madhi; Alane Izu; Marta C Nunes; Avye Violari; Mark F Cotton; Patrick Jean-Philippe; Keith P Klugman; Anne von Gottberg; Nadia van Niekerk; Peter V Adrian Journal: Vaccine Date: 2015-04-21 Impact factor: 3.641
Authors: Shabir A Madhi; Alane Izu; Avye Violari; Mark F Cotton; Ravindre Panchia; Els Dobbels; Poonam Sewraj; Nadia van Niekerk; Patrick Jean-Philippe; Peter V Adrian Journal: Vaccine Date: 2012-12-08 Impact factor: 3.641
Authors: E M Molyneux; M Tembo; K Kayira; L Bwanaisa; J Mweneychanya; A Njobvu; H Forsyth; S Rogerson; A L Walsh; M E Molyneux Journal: Arch Dis Child Date: 2003-12 Impact factor: 3.791
Authors: David W McCormick; Mark L Wilson; Limangeni Mankhambo; Ajib Phiri; Yamikani Chimalizeni; Kondwani Kawaza; Brigitte Denis; Enitan D Carrol; Elizabeth M Molyneux Journal: Pediatr Infect Dis J Date: 2013-02 Impact factor: 2.129